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Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the
second leading cause of cancer death. Hepatitis B virus (HBV) infection is one of the
major risk factors for the development of HCC in the world. Most of the burden of
disease (85%) is observed in the HBV endemic regions. Chronic infection with HBV
predisposes patients with or without cirrhosis to HCC. Patients with high HBV DNA
levels are at an increased risk for HCC. Studies have shown that the suppression of HBV
with anti-viral therapy (nucleos(t)ide analogs) (NAs) decreases the incidence of HCC
but does not eliminate the risk entirely. Chronic viral suppression alone is not sufficient
treatment to prevent HCC development. Therefore, along with NAs, treatment may
need to include targeting the cccDNA and inhibiting the viral entry into the newly
formed hepatocytes and T-cell vaccine which specifically targets HBV and enhancing
innate immunity with Toll-like receptor agonist. With all of these working together, we
may achieve the goal of HBV cure.
Keywords: HBV, HCC, nucleos(t)ide analogs, antiviral treatment, prevention of HCC,
HBV cure, hepatocarcinogenesis
1. Hepatitis B virus (HBV)
1.1. The discovery of HBV
Following the “icteric epidemic” in the 1880s, viral hepatitis was recognized as infectious in
nature  [1].  The  discovery  of  HBV did  not  occur  until  1965  when Baruch  Blumberg,  an
American  physician  and  geneticist,  found a  unique  antigen  in  the  serum of  Australian
aborigines (Australia Antigen, AuAg) that reacted with the serum of hemophiliacs [2, 3]. This
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antigen AuAg is now recognized as the hepatitis B surface antigen (HBsAg). Later, the link
between viral hepatitis and this newly discovered antigen was firmly established when a
technician in Blumberg’s laboratory developed acute hepatitis [4]. Blumberg was awarded the
Nobel Prize in Medicine in 1976 for his discovery of HBV.
Dane et al. identified the entire viral particle using electron microscopy in the 1970s [5].
Subsequently, in 1971, Blumberg and Millman developed a blood test to start screening blood
donations for HBV [6]. In 1980, the FDA approved the first commercially available HBV vaccine
once the genome of HBV was sequenced [7, 8]. While this first generation vaccine is no longer
available in the United States, a recombinant HBV vaccine has been in use since 1986. A strong
association between HBV and hepatocellular carcinoma (HCC) was described by Beasley et al.
in their landmark study of 22,707 men in Taiwan [9]. Therefore, this vaccine has been desig-
nated by the World Health Organization as a bonafide “cancer vaccine”.
1.2. HBV epidemiology
From a global view, a recent meta-analysis shows that the worldwide HBsAg prevalence is
3.61% [10]. There are over 248 million people currently living with chronic hepatitis B (CHB).
Africa has the highest endemicity, with an HBsAg prevalence of 8.83%. However, the country
with the largest number of people living with CHB is China with 95 million people, with an
HBsAg prevalence of 5.49%. India and Nigeria have the second and third highest population
of HBsAg (+) individuals, respectively, at 17 and 15 million people.
Chronic hepatitis B is a major risk factor for the development of hepatocellular carcinoma. A
study in New York City found that Korean males had the highest rate of liver cancer–related
mortality compared with all racial/ethnic groups. In fact, liver cancer was the second and third
cause of cancer-related deaths in NYC Chinese and Korean men, respectively [11]. The Asian
American Hepatitis B Program (AAHBP), a large community-based program in New York
City, has found 13.3% HBsAg positivity among over 4000 newly screened individuals born in
Asia [12].
2. HBV carcinogenesis
2.1. Risk of HCC from HBV infection
In a landmark paper in 1981, Beasley et al. established the association between HBV and HCC
in 22,000 HBsAg (+) Taiwanese men. Compared to uninfected controls, their relative risk for
HCC was found to be 63 [9]. Since then, co-infection with HCV [13], family history of HCC [14],
alcohol intake [15], HBV genotype C greater than B [16, 17], and core promoter mutations [18,
19] have all been identified as risk factors for HCC development.
In highly endemic areas, HBV transmission is nearly all from mother to newborn and as many
as 90% of infected babies develop chronic infections [20]. This differs from areas that have a
low prevalence of HBV, where transmission is horizontal through sexual and parenteral routes
in adulthood. More than 90% of these cases of acute HBV infection resolve spontaneously and
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do not lead to chronic infections. Longer periods of chronic HBV infection contribute to a
higher risk for HCC; therefore, endemic areas have a higher incidence of HCC.
Approximately 25% of those chronically infected people with HBV will develop HCC [21]. In
addition to the earlier report by Beasley et al. [9], Franceschi et al. also reported a 30-fold
increased risk of HCC in chronic HBV carriers [22]. A systematic review estimated the
incidence rates of HCC in subjects with chronic HBV infection in East Asian countries to be
0.2 per 100 person-years in inactive carriers (HBsAg-positive but with normal levels of ALT),
0.6 person-years for those with chronic HBV infection without cirrhosis, and 3.7 person-years
for those with compensated cirrhosis [23]. HBV can cause HCC in the absence of cirrhosis
though 70–90% of HBV-related HCC occur in patients with cirrhosis [24].
The risk of HCC is increased in patients with higher levels of HBV replication. One large study
followed 11,893 Taiwanese men for a mean of 8.5 years to evaluate the effect of HBV replication
on the risk of HCC. The incidence rate of HCC was 1169 per 100,000 person-years among men
who were positive for both HBsAg and HBeAg, 324 per 100,000 person-years for those who
were only HBsAg-positive, and 39 per 100,000 person-years for those who were HBsAg-
negative [25]. The relative risks of HCC among men who were positive for both HBsAg and
HBeAg were increased 60-fold compared to 10-fold among those who were only HBsAg
positive [25]. Another prospective study from Taiwan reported that in a cohort of 3653 HBsAg-
positive participants, the incidence of cirrhosis and HCC increased in proportion to the HBV
DNA level, from <300 copies/mL at 0.74% incidence to ≥1,000,000 copies/mL at 13.50%
incidence over 13 years of follow up [26]. Furthermore, inactive carriers of HBV (HBeAg
negative, HBV DNA <10,000 copies/mL, normal liver enzyme levels, no cirrhosis) are still at a
5-fold greater risk for HCC than HBsAg-negative controls [27].
2.2. Entry of HBV DNA into host cells
Hepatitis B virus is an enveloped DNA virus belonging to the Hepadnaviridae family. HBV
contains a partially double-stranded circular DNA genome (rcDNA) [28]. HBV recognizes
highly sulfated heparin sulfate proteoglycans (HSPGs) on the surface of liver cells, allowing
the virus to be highly hepatotropic [29]. When HBsAg binds a liver-specific receptor named
sodium taurocholate cotransporting polypeptide (NTCP or SLC10A1) during an infection, the
virus gains entry into its host cell [30].
Upon entering the human hepatocyte, rcDNA becomes a covalently closed circular DNA
(cccDNA) in the nucleus. This cccDNA functions as a template for transcription of all four viral
mRNAs, which then translate all seven HBV proteins [28]. The largest viral mRNA transcript
encodes the viral polymerase and is a template for DNA [31]. Current HBV antiviral medica-
tions thwart this step of the viral replication [32].
2.3. HBV X protein
The HBV X protein (HBx) is a 154 amino acid polypeptide with a mass of 17 kDa. Its role in
the development of HCC is critical. HBx regulates cellular transcription, protein degradation,
and cellular proliferation and apoptosis. HBx acts on cellular promoters by protein-protein
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interactions instead of binding directly to DNA. HBx can downregulate Wnt/β-catenin
expression and suppress cell growth by not only repressing cell proliferation but also trigger-
ing cell apoptosis [33]. HBx protein also interacts with the tumor suppressor adenomatous
polyposis coli to activate Wnt/β-catenin signaling, which upregulates the epithelial cell
adhesion molecule in HCC cells to promote tumor initiation [34, 35]. Therefore, HBx activation
of Wnt/β-catenin may directly promote the transformation of hepatocytes into cancer initiat-
ing cells [36]. Overall, the seemingly contradictory roles of HBx in regulating apoptosis
demonstrate the complexity of hepatocarcinogenesis.
There are numerous ways in which HBx may induce anti-apoptotic effects. The most salient
is its ability to inhibit p-53-mediated apoptosis. HBx may increase the expression of telomerase
reverse transcriptase and telomerase activity, thus prolonging the lifespan of hepatocytes and
leading to malignant transformation [36]. In addition, carboxyl-terminal (C-terminal) truncat-
ed HBx protein loses its proapoptotic properties and may enhance the protein’s ability to
transform oncogenes [36].
2.4. Integration of HBV DNA into host DNA
HBx truncation occurs with HBV integration into host DNA. The 3′-end of HBx is the preferred
region of HBV genome involved in integration. When HBV integrates, the 3′-end of HBx is
often deleted. Therefore, HBV integration is an important step in HCC development [37]. The
C-terminal region produced by HBx truncation also contributes to HCC development. The C-
terminal region has been suggested to be required for ROS production and 8-oxoguanine
formation, biomarkers of oxidative stress [38]. The 24 amino acids truncated at the C-terminal
end play a role in increasing cell invasiveness and metastasis in HCC through activation of
MMP10 by C-Jun signaling [39]. Lastly, C-terminal truncated HBx has been reported to directly
regulate miRNA transcription and promote hepatocellular proliferation [40].
3. Natural history
HBV carriers often are asymptomatic without significant liver injury because HBV replication
in itself is not directly cytotoxic to hepatocytes [21, 41]. Hepatocellular injury occurs largely
from host immune responses, both through major-histocompatibility-complex (MHC) class II-
restricted, CD4+ helper T cells and MHC class I-restricted, CD8+ cytotoxic T lymphocytes [21,
42]. Four distinct phases comprise the natural history of HBV infection.
3.1. Acute “immune tolerant” phase
In the acute phase of infection with HBV, the “immune tolerant” phase is HBeAg (+) with high
viral loads, normal serum alanine aminotransferase (ALT), and near normal liver histology
[43]. When HBV is acquired in adulthood, this phase is very short [44]; however, perinatal and
early childhood infection lead to a long “immune-tolerant” phase [45, 46]. The risk of pro-
gression to chronic carrier state differs greatly between those infected perinatally (90%) and
as an adult (<1%) [44, 47, 48]. At the current time, antiviral treatment is not recommended
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during the immune-tolerant phase but rather for the immune clearance phase. Interestingly,
some recent reports have shown evidence of immune reactivity during the immune-tolerant
stage [49–51]. As was presented by Zoulim and Mason, there is an argument to consider earlier
treatment of CHB in order to prevent HCC [52].
3.2. “Immune clearance” phase
The “immune clearance” phase, developing during adolescence, is characterized by high viral
load, HBeAg (+), and elevated ALT. Antiviral therapy is usually recommended during this
phase. The salient feature of this phase is elevated ALT levels, which is a result of T-cell
immune-mediated lysis of hepatocytes [53, 54]. The frequency of flares and duration of this
phase are correlated with the risk of cirrhosis and HCC [55, 56]. High ALT level is a marker of
vigorous host immune response, which is correlated with spontaneous HBeAg seroconver-
sion. HBeAg seroconversion to anti-HBe is a pertinent outcome of this phase [57, 58].
3.3. “Inactive carrier” phase
Following HBeAg seroconversion, an “inactive HBsAg carrier” phase begins. It is marked by
HBeAg (−), anti-HBe (+), normal ALT, and low or undetectable viral load [59]. Liver biopsy at
this time would show mild hepatitis, minimal fibrosis, but cirrhosis may also be seen in patients
who have experienced severe liver injury in the previous “immune clearance” phase [60].
Antiviral therapy is not indicated in this phase, but patients do need regular screening for HCC
given the persistent risk while remaining positive for HBsAg and anti-HBc (IgG). Spontaneous
seroclearance of HBsAg at a yearly incidence of 0.7–2.4% may happen after patients become
HBeAg (−) [57, 61]. This phase may persist indefinitely.
3.4. “Reactivation/HBeAg-negative chronic hepatitis” phase
The last phase in the natural history of HBV infection is more recently recognized. The
“reactivation of HBV replication/HBeAg-negative chronic hepatitis B” stage, also known as
“e-CHB”, is marked by HBeAg (−), anti-HBe (+), detectable viral load, elevated ALT, and
continued necroinflammation on histology [62]. Patients may enter the “e-CHB” phase after
some years in the “inactive carrier” phase or directly progress from HBeAg (+) chronic hepatitis
to HBeAg (−) chronic hepatitis [63]. Many mutations in the viral core promoter and pre-core
regions inhibit the synthesis of HBeAg without affecting HBV replication. Nucleotide 1896 is
one of the most studied mutations associated with e-CHB in the pre-core region [64].
4. Prevention of HCC
4.1. Results of vaccination
Taiwan, a country with a high prevalence of chronic HBV, instituted a nationwide HBV
vaccination program in 1984 for all citizens ranging from neonates to adults. A landmark paper
published in the New England Journal of Medicine in 1997 reports the effect of vaccination on
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childhood HCC in Taiwan [65]. In 1984, the prevalence of seropositivity of HBsAg was 10.6%
in six-year olds. Ten years after launching the vaccination campaign, this prevalence was
reduced to <1% in six-year olds by 1994. The incidence of HCC in children ages 6–9 significantly
declined from 0.52 per 100,000 for those born between 1974 and 1984 to 0.13 for those born
between 1984 and 1986.
Given the availability of national health records, Taiwan is a country with tremendous potential
for public health and epidemiological investigations. A newer study from the same group
published recently re-examines the effect of HBV vaccination by comparing the rate of HCC
in different time periods [66]. Between 1983 and 2011, 1509 patients were diagnosed with HCC.
1343 were born before and 166 were born after the HBV vaccination program began. The
relative risk for HCC in patients 6–9 years old, 10–14 years old, 15–19 years old, and 20–26
years old who were vaccinated vs. unvaccinated were 0.26, 0.34, 0.37, and 0.42, respectively.
Out of the 166 cases of HCC that occurred after HBV vaccination began in Taiwan, the two
strongest risk factors were transmission of HBV from highly infectious mothers and incom-
plete immunization.
At this point, 180 countries have introduced infant HBV vaccination, and the global HBV
vaccination coverage rate for the third dose is about 78% [67]. HBV vaccines are usually
administered in three doses, with the second dose given one month after the first dose and the
third dose given six months after the first dose. The dose recommended for adults is 10–20
μg and for infants and children 5–10 μg. With regard to the immunogenicity of HBV vaccines,
over 90% of infants, children, and adolescents have protective serum anti-HBs antibody
concentrations (>10 mIU/mL) after the vaccine series has been completed. However, host
factors such as age older than 30, obesity, immunosuppression, and smoking have been linked
to inadequate immunogenicity to the HBV vaccine.
Vaccination is most important for infants, particularly those born to HBsAg (+) mothers. In
addition, the WHO recommends high-risk groups should also be vaccinated as well, includ-
ing [1] people who frequently require blood transfusions, such as dialysis patients and
recipients of solid organ transplantations [2]; people interned in prisons [3]; IV drug users [4];
household and sexual contacts of people with chronic HBV infection [5]; people with multiple
sexual partners, health-care workers, and others who are exposed to blood or blood products
through work [6]; and travelers who have not completed their HBV vaccine series. Although
post-vaccination testing for immunity is not generally recommended, it has been the practice
at our institution to conduct post-vaccination test to confirm the presence of anti-HBs at the
protective level (>10 IU). For those who fail to produce antibody, it is important to rule out the
occult HBV infection not uncommonly seen among the family members of HBV patients.
4.2. Surveillance for HCC
It is generally recommended to perform HCC surveillance in those with CHB and especially
if the patient has cirrhosis. CHB is an independent risk factor for the development of HCC,
which can occur even without cirrhosis. The surveillance method includes imaging, wheth-
er triple-phase CT or MRI with contrast, should occur every 6 months. The evidence for
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serological testing for alpha fetal protein (AFP) in surveillance for HCC is unclear; however,
at our institution it is obtained at 6-month intervals with imaging.
A recent study shows the importance of HCC surveillance even in those with seroclearance of
HBsAg [68]. In a retrospective analysis of 829 patients (mean age: 52.3 years; 575 males; 98 with
cirrhosis) after HBsAg seroclearance, the estimated annual incidence of HCC was 2.85% and
0.29% in patients with and without cirrhosis, respectively. In non-cirrhotic patients, the annual
rate of HCC was higher in males than females (0.40% vs. 0%, respectively). The study concludes
that HCC surveillance should be considered for cirrhotic patients and non-cirrhotic male
patients over age 50, even after HBsAg seroclearance, especially those infected with HBV
genotype C.
4.3. Prevention of recurrent HCC post-resection, transplantation, and local tumor ablation
Antiviral therapy after tumor resection aims to improve prognosis by suppressing viral
replication. Recent evidence indicates high serum HBV DNA levels, either preoperatively or
postoperatively, is associated with a higher risk of HCC recurrence [69]. Furthermore, the
incidence of HCC recurrence was significantly higher in patients who experienced acute
postoperative exacerbations of hepatitis with high-serum concentrations of HBV DNA and
sustained HBsAg expression postoperatively [70]. Antiviral therapy has been shown to induce
the remission of active hepatitis, maintain liver function, and increase the likelihood of
successful treatment for HCC recurrence even if recurrence developed after curative resection
[71]. In addition, high levels of HBV DNA are significantly associated with shorter survival
times, with the cause of death being HCC recurrence [71]. A recent meta-analysis shows that
antiviral therapy with nucleos(t)ide analogs (NAs) reduces HCC-related mortality and HCC
recurrence postoperatively, and improves overall survival in patients with HBV-related HCC
[72].
There is a lack of evidence to guide the management of HBV after liver transplantation for
HBV-related HCC; however, lifelong antivirals are used in most centers. In the case of
transplantation for HBV cirrhosis, recurrent HBV may lead to graft loss and poor post-
transplant survival. There is a direct relationship between the HBV VL at time of transplanta-
tion and the rate of HBV recurrence [73]. Since the study by Samuel et al. [74], hepatitis B
immune globulin (HBIG) has been use as prophylaxis against HBV recurrence after liver
transplantation for HBV cirrhosis.
We have reported favorable effects of antiviral therapy on the survival of HCC patients
following local tumor ablation through interventional radiology [75]. We included 25 patients,
who met criteria with a single HCC ≤ 7 cm and underwent tumor ablation with curative intent.
Sixteen patients (diagnosed 1999 and after) received antiviral therapy and nine patients
(diagnosed before 1999) did not. While there was no difference in their median tumor size and
AFP, the survival was significantly different (p < 0.001). The median survival of the untreated
was 16 months while that of the treated was 80 months. Fourteen of 16 treated patients are
alive to date with two longest survivors alive for ≥151 months. Overall, there is evidence for
lifelong antiviral therapy for patients with HCC treated with resection, transplantation, or local
regional therapy.
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5. Current treatment of hepatitis B
Since the advent of antiviral drugs, survival of patients with HBV has been remarkably
improved. Current treatments for hepatitis B include nucleos(t)ide analogs (lamivudine,
adefovir, entecavir, telbivudine, and tenofovir) and an interferon [pegylated-interferon
alpha-2a (peg-IFN α-2a)] (Table 1) [4, 76]. The ultimate goal in the treatment of chronic hepatitis
B is to prevent the development of HCC.
Name  Trade name Strengths Weaknesses Approved
Pegylated
interferon-2a 
Pegasys Finite duration of treatment
Durable response post-treatment
No known resistance
Needle injection
High cost
65–70% fail to respond
Significant side effects
1991
2005
Lamivudine Epivir Oral
Safe with negligible side effects
Effective and safe in pregnancy
Least expensive
Long-term treatment is necessary
High incidence of resistance
1998
Adefovir
dipivoxil
Hepsera Oral
Low resistance
Long-term treatment is necessary
Long-term treatment for renal toxicity
Less potent than other treatments
2002
Entecavir Baraclude Oral
Potent viral suppression
Safe with negligible side effects
Low resistance
Long-term treatment is necessary
High cost
2005
Telbivudine Tyzeka Oral
Potent viral suppression
Effective and safe in pregnancy
Long-term treatment is necessary
High incidence of resistance
2006
Tenofovir Viread Oral
Potent viral suppression
Safe with negligible side effects
No known resistance so far
Effective and safe in pregnancy
Long-term treatment is necessary 2008
Adapted from Halegoua-De Marzio and Hann [4].
Table 1. Current approved drugs for treatment of HBV.
5.1. Pegylated-interferon alpha-2a
Pegylated-interferon alpha-2a (peg-IFN α-2a) has replaced interferon alpha-2b due to better
pharmacokinetic properties, weekly injection schedule, and similar efficacy. Its major mech-
anism of action is in immune modulation with a weak antiviral effect [77]. Peg-IFN α-2a has
the highest rate of sustained response after 1 year of therapy, with a 27% rate of HBeAg
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seroconversion and 25% rate of loss of HBV DNA after 48 weeks of treatment [78, 79]. After
18 months of follow up, 4–6% of patients showed serum positivity for anti-HBs and had
loss of HBsAg [78, 79]. Even after the end of treatment, 12–65% of patients had seroclear-
ance of HBsAg within 5 years of losing HBeAg [80, 81]. A study of 542 patients, who re-
ceived the medication for 48 weeks, shows patients with the best response include genotype
A with HBV DNA <9 log10 copies/mL or ALT ≥ 2×ULN, or genotype B and C with ALT ≥
2×ULN and low HBV DNA (<9 log10 copies/mL) [84]. Remission long after discontinuing
therapy was associated with an early virological response, defined as suppressing levels to
below 105 copies/mL within the first 2 weeks of therapy or >2 log10 decrease in serum HBV
DNA [82, 83].
Peg-IFN α-2a only makes up about 10% of all hepatitis B prescriptions in the United States due
to its substantial side effect profile and need for administration by injection [85].
5.2. Lamivudine
Approved by the Food and Drug Administration (FDA), lamivudine is a nucleoside analog
reverse transcriptase inhibitor. Due to availability of other oral antivirals that have higher
genetic barriers to resistance, lamivudine is not commonly used today. The most common
reasons for its use currently are during pregnancy in HBsAg (+) women to perinatal transmis-
sion and during chemotherapy and immunosuppression to prevent reactivation of HBV in
HBsAg (+) patients.
With 12 months of treatment, lamivudine is associated with 16–18% rate of HBeAg serocon-
version [86]. In HBeAg (+) patients, the rate of HBeAg seroconversion increases with the
duration of treatment, from 17% at 1 year to 27% at 2 years to 47% at 4 years [87]. Therapy for
1 year also results in 60–70% HBV DNA suppression in HBeAg (−) patients with chronic
hepatitis B [88].
Lamivudine has been shown to decrease the rate of fibrosis and the incidence of HCC [89]. A
study of 651 Asian patients with advanced fibrosis was stopped prematurely at 32 months
because a significantly lower proportion of the lamivudine-treated group reached the primary
endpoint of development of hepatic decompensation, HCC, or death from liver disease
compared to placebo (7.8% vs. 17.7%) [89]. Lamivudine-treated patients have been observed
to have a significant reduction in the incidence of HCC [90]. Reversal of fibrosis was signifi-
cantly more likely to be seen on histology after 52 weeks of treatment with lamivudine than
placebo [87].
Despite these positive attributes, there is a decrease in lamivudine usage due to its resistance
profile. A large-scale safety study showed resistance rates of 23% at one year and 67% at five
years of therapy in HBeAg (+) patients [91]. In a small study at our institution, lower resistance
rate of 3% at one year and 10% at two years was found when 150 mg dose of lamivudine was
used [92]. Pretreatment HBV DNA level is the most important factor for lamivudine resistance.
Tenofovir has been shown to have stronger antiviral effect than adefovir against lamivudine-
resistant HBV [93]. Furthermore, tenofovir monotherapy has been shown to be superior to
adefovir and lamivudine combination therapy in lamivudine-resistant HBV [94].
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5.3. Adefovir dipivoxil
Approved in 2002 by the FDA, adefovir dipivoxil is a nucleotide analog reverse transcriptase
inhibitor. Treatment with adefovir for one year in HBeAg (+) patients leads to a 12% HBeAg
seroconversion and 53% histological improvement [89, 95, 96]. Furthermore, HBeAg serocon-
version is sustained in 91% of patients [97]. Development of resistance is associated with
persistent viremia after 48 weeks of therapy. Rates of adefovir resistance at 1, 2, 4, and 5 years
of therapy have been reported at 0%, 3%, 18%, and 29%, respectively [98]. Nevertheless,
adefovir use is declining with the arrival of newer medications.
5.4. Entecavir
Approved by the FDA in 2005 for the treatment of CHB, entecavir is a nucleoside analog that
inhibits HBV polymerase. It is administered as an oral dose of 0.5 mg/day, resulting in superior
reduction of HBV DNA levels compared to lamivudine (6.98 log10 copies/mL vs. 5.4 log10
copies/mL) [99]. In a phase three clinical trial entecavir to lamivudine, those who received 52
weeks of entecavir achieved better virological response with HBV DNA < 400 copies/mL (67%
entecavir vs. 36% lamivudine), normalization of ALT (78% vs. 70%), and histological improve-
ment (72% vs. 62%) [99]. While entecavir is superior to lamivudine in HBeAg (−) patients, it
does require indefinite treatment to maintain viral suppression and prevent relapse [100, 101].
After 6 years of therapy, 96% of HBeAg (+) CHB patients had histological improvement and
88% showed improved fibrosis scores even in cirrhosis [102]. Continuous entecavir treatment
for up to 5 years in HBeAg (+) patients has been able to maintain HBV DNA suppression <300
copies/mL in 94% of patients [103].
In comparison to adefovir, entecavir has been shown to achieve viral suppression more rapidly
within 14 days of initiating therapy [98]. Entecavir also has a higher rate of HBV clearance (58%
vs. 19%) and ALT normalization (76% vs. 63%) when compared with adefovir after 48 weeks
of treatment. No significant difference was observed in the rate of HBeAg loss or HBeAg
seroconversion [104].
The incidence of HCC has been shown to decrease in entecavir-treated patients compared to
non-treated. The five-year cumulative HCC incidence was 3.7% and 13.7% for entecavir-treated
and control groups, respectively [105]. HBsAg loss has been associated with entecavir
treatment [106, 107]. Compared to lamivudine treatment in HBeAg (+) patients, 96 weeks of
entecavir treatment resulted in HBsAg loss in 5% of patients and 3% of lamivudine-treated
patients [108]. Unlike HBeAg (+) patients, HBeAg (−) patients show no significant HBsAg loss
on entecavir [109].
The biggest advantage of entecavir is its high genetic barrier and low resistance profile. The
cumulative incidence of resistance after 6 years of entecavir in nucleoside-naïve patients is low
at 1.2%. However, in lamivudine-refractory patients, the rate of resistance to entecavir is 57%
at 6 years [110].
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5.5. Telbivudine
Telbivudine is an L-nucleoside that is structurally related to lamivudine; it was approved by
the FDA in 2006. It specifically inhibits HBV viral DNA synthesis, and it has been shown to be
superior to lamivudine in both HBeAg (+) and HBeAg (−) patients with CHB. The serocon-
version of HBeAg with telbivudine was found to be 22% and 30% at 1 and 2 years, respectively,
in patients who are HBeAg (+) [111, 112]. In these patients, suppression of HBV DNA < 300
copies/mL was 60% and 56% at 1 and 2 years, respectively [105, 106]. Furthermore, recent
evidence shows telbivudine has renoprotective effects, both in preventing adefovir-induced
nephrotoxicity and improving renal function in liver transplant patients [113–116].
However, resistance to telbivudine has been reported at 21.6% and 8.6% after 2 years of therapy
in HBeAg (+) and HBeAg (−) patients [117]. Predictive factors for response to telbivudine
include ALT > 2×ULN at baseline or HBV DNA < 9 log10 copies/mL in HBeAg (+) patients [118,
119]. Telbivudine treatment has good therapeutic result in patients with low baseline HBV
DNA and negative HBV DNA at week 24 [118].
Telbivudine is a pregnancy category B medication. A study of 186 pregnant Asian women with
HBV DNA > 6,000,000 copies/mL, half received telbivudine from second trimester of preg-
nancy until 4 weeks postpartum and all infants received hepatitis B immune globulin (HBIG)
within 24 h of birth, telbivudine treatment showed better outcomes compared with the control
group with more women achieving undetectable HBV DNA (30% vs. 0%) [120]. Importantly,
no infants born to women in the treatment group were HBsAg (+) compared to 8.7% in the
control group.
5.6. Tenofovir
Tenofovir is the most recent nucleotide analog to be approved by the FDA in 2008. It is similar
in structure to adefovir but more potent. Compared with adefovir in HBeAg (+) patients, 48
weeks of tenofovir led to more normalization of ALT (68% vs. 54%), stronger viral suppression
defined as < 400 copies/mL (76% vs. 13%), histological improvement (67% vs. 12%), and HBsAg
loss (3.2% vs. 0%) [121]. After 7 years of therapy, 99.3% of patients maintained viral suppres-
sion, 80% of patients achieved normalization of ALT, and no resistance was detected. In
patients who are HBeAg (+), 54.5% achieved HBeAg (−) and 11.8% HBsAg (−). In HBeAg (−)
patients, only 0.3% achieved HBsAg loss. There were 10 patients (1.7%) who had elevated
serum creatinine ≥ 0.5 mg/dL above baseline while on tenofovir, and no significant changes in
bone density was observed. HCC incidence has been recently reported to be decreased in
tenofovir-treated HBV patients [122].
5.7. Hepatitis B during pregnancy
Newborns to mothers with CHB should receive hepatitis B immune globulin and the first
dose of hepatitis B vaccine within 12 h of birth to prevent vertical transmission of HBV. Two
subsequent doses of hepatitis B vaccine are administered within 6–12 months of age. Never-
theless, 7–32% of infants born to carrier mothers with high viral loads still become HBsAg
(+) despite passive-active immunoprophylaxis [123, 124]. A Chinese study shows vertical
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transmission despite immunoprophylaxis failures occurred in HBeAg (+) mothers with
HBV DNA levels >6 log10 copies/mL (>200,000 IU/mL) [125]. Therefore, it is very important
to consider antiviral therapy in pregnant women with high levels of viremia, especially for
mothers with infants who had previously failed immunoprophylaxis.
Both lamivudine and telbivudine have been used during the latter stages of pregnancy. They
have comparable efficacy and safety in mothers and their newborns during 12 month post-
partum observations, where the rate of vertical transmission was seen to be reduced when
HBeAg (+) mothers with high viral loads received either lamivudine or telbivudine during the
third trimester of pregnancy [121, 123, 126]. Currently, the use of oral antiviral agents during
the first and second trimesters of pregnancy is not recommended.
Maternal HBV reactivation during pregnancy is uncommon but if encountered, antiviral
therapy should be considered, especially if the reactivation is severe [126, 127]. Breastfeeding
is not contraindicated for mothers who are on antiviral treatment as these medications are
minimally excreted in breast milk and unlikely to cause significant toxicity [128].
5.8. Hepatitis B reactivation during chemotherapy or immunosuppressive therapy
With immunosuppressive therapy such as rituximab, chemotherapy, or corticosteroids, HBV
reactivation can occur in HBsAg (+) carriers. Immunosuppression allows HBV replication and
infection of hepatocytes, and reactivation usually occurs after discontinuation or withdrawal
of immunosuppression as the immune system is reconstituted [129]. Reactivation leads to acute
hepatitis, characterized by high levels of ALT and serum HBV DNA.
Lamivudine has been shown to be effective for prophylaxis of HBV reactivation during
chemotherapy in a meta-analysis of 14 clinical trials [129]. It has been most effective when used
for patients with low (<2000 IU/mL, < 104 copies/ml) or undetectable HBV DNA level and/or
receiving a short course of immunosuppression for less than 6 months. Furthermore, for
patients who are compliant with the medication, low resistance has been observed with a dose
of 150 mg daily [92]. On the other hand, if the patient is undergoing a long course of chemo-
therapy or has a high viral load, nucleos(t)ide analogs such as tenofovir or entecavir are
recommended due to their lower rate of resistance.
Asian patients should be screened for HBsAg prior to the initiation of chemotherapy or
immunosuppressive therapy due to the high prevalence of CHB in Asia. These patients
may be silent HBsAg (+) carriers who are unaware of their HBV status [130]. Patients who
are HBsAg (−) but anti-HBc (+) should be tested for serum HBV DNA [80]. All HBsAg
(+) patients who require immunosuppression or undergo bone marrow transplantation
should be treated with antiviral prophylaxis [131]. Furthermore, any anti-HBc (+) patients,
whether anti-HBs (+) or anti-HBs (−), who require such therapies should be considered as
candidates for antiviral treatment [132]. Guidelines proposed by different societies for
preventing HBV reactivation during immunosuppression were reviewed and summarized
(Table 2) [132–136].
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Society  Population (HBV DNA) Prophylaxis Prophylaxis type
AASLD
[132] 
Baseline HBV DNA <2000 IU/ml Antiviral prophylaxis
recommended
LAM or telbivudine (if IS < 12 months) or
ETV > adefovir (if IS > 12 months)
Baseline HBV DNA >2000 IU/ml Antiviral prophylaxis
recommended
LAM or telbivudine (if IS < 12 months) or
ETV > adefovir (if IS > 12 months)
EASL [133]  Baseline HBV DNA <2000 IU/ml Antiviral prophylaxis
recommended
LAM
Baseline HBV DNA >2000 IU/ml Antiviral prophylaxis
recommended
Antiviral w/ high barrier to resistance
AGA [134] High risk (>10% HBVr incidence) Antiviral prophylaxis
recommended
Antiviral w/ high barrier to resistance
Moderate risk (1–10% HBVr
incidence)
Antiviral prophylaxis
suggested or monitor
Antiviral w/ high barrier to resistance
Low risk (<1% HBVr incidence) None N/A
APASL [135] All HBsAg (+) patients Antiviral prophylaxis
recommended
ETV/TDF > LAM
AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of the Liver;
AGA, American Gastroenterological Association; APASL, the Asian Pacific Association for the Study of the Liver;
LAM, lamivudine; ETV, entecavir; TDF, tenofovir. Adapted from Wu and Hann [136].
Table 2. HBsAg (+) antiviral prophylactic guidelines for immunosuppression (IS) by society.
6. Seeking a cure for HBV
Firstly, defining the concept of HBV cure is important. The ultimate goal is eradication of
cccDNA, also known as complete cure. However, functional cure (clearance of HBsAg,
cessation of liver disease, even with persistent liver cccDNA) is achievable with current
antivirals. Nonetheless, without eradication of HBV cccDNA, there remains a risk for HCC
development even after years of successful antiviral treatment, especially in those with
cirrhosis. Recent development of novel in vitro models has enriched the study of HBV patho-
genesis and new antiviral strategies including immunotherapies.
Many new agents are in the pipeline. These include direct-acting antivirals (DAAs) and host-
targeting agents (HTAs), which focus on targeting cccDNA in a number of different ways [28].
DAAs against HBV currently in development include novel polymerase inhibitors, capsid
inhibitors, rcDNA-cccDNA conversion inhibitors, DNA cleavage enzymes, and small inter-
fering RNA (siRNA)-based agents (Table 3) [137]. In addition, HTAs target sodium taurocho-
late co-transporting polypeptide (NTCP), host involvement in HBV secretion and budding,
and immune responses (innate and adaptive) [28]. Novel agents to eradicate HBV would be a
very important cancer cure given the role of hepatitis B virus in carcinogenesis.
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Family/drug name  Mechanism  Status  Company
Nucleoside/nucleotide analogs
Clevudine Inhibits viral DNA polymerase Approved in S. Korea and
Philippines
Bukwang/Eisai
MIV-210 (lagociclovirvalactate) Inhibits viral DNA polymerase Phase II Medivir/Daewoong
Besifovir (LB80380) Inhibits viral DNA polymerase Phase IIb LG Life Sciences
Tenofovir alafenamide (GS-7340) Inhibits viral DNA polymerase Phase Ib Gilead
CMX157 Inhibits viral DNA polymerase Phase I Chimerix
AGX-1009 Inhibits viral DNA polymerase Phase I, China Agenix
Non-nucleoside antivirals
Myrcludex-B Entry inhibitor Phase Ia, Germany Myr-GmbH
Bay 41-4109 Inhibits viral nucleocapsid Phase I, Germany AiCuris
GLS 4 Inhibits viral nucleocapsid Phase I, China Sunshine Lake
Phenylpropenamides Inhibits viral encapsidation Preclinical
REP 9 AC HBsAg release inhibitor Phase Ib REPLICor, Inc.
Nitazoxanide (alinia) Small molecule Preclinical Romark Labs
dd-RNAi compound Gene silencing Preclinical Benitec/Biomics
ARC-520 RNAi gene silencer Phase I Arrowhead Research
Immune-based
Zadaxin (thymosin-alpha 1) Immunomodulator Orphan drug approval in
United States for liver
cancer 
SciClone
NOV-205 (BAM 205) Immunomodulator Approved in Russia Novelos
GS-9620 TLR7-agonist Phase I Gilead
GI-13020 HBV antigen Preclinical Global Immune
DV-601 Therapeutic HBV vaccine Phase Ib Dynavax
Adapted from Wang and Chen [137].
Table 3. Emerging drugs against HBV.
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